doi:10.4239/wjd.v5.i4.444 8
Tirzepatide has demonstrated superior efficacy in both weight loss and blood glucose control compared to semaglutide (Aronne et al., 2025), highlighting the therapeutic potential of multi-agonist strategies
While many drugs in this class were initially approved to treat type 2 diabetes, they have also been approved for weight loss
The weighted incidence of suicidality was 3.9 and 3.7 for every 1,000 person-years among GLP-1 receptor agonist and DPP-4 inhibitor users, respectively
Accessed November 12, 2025
HF may cause kidney dysfunction through multiple mechanisms, including neurohormonal activation, inflammation and oxidative stress, with consequent reductions in renal perfusion and augmentation of renal venous pressure